LU92883I2 - Sonidégib ou un sel, hydrate ou solvate pharmaceutiquement acceptable qui en dérive - Google Patents

Sonidégib ou un sel, hydrate ou solvate pharmaceutiquement acceptable qui en dérive Download PDF

Info

Publication number
LU92883I2
LU92883I2 LU92883C LU92883C LU92883I2 LU 92883 I2 LU92883 I2 LU 92883I2 LU 92883 C LU92883 C LU 92883C LU 92883 C LU92883 C LU 92883C LU 92883 I2 LU92883 I2 LU 92883I2
Authority
LU
Luxembourg
Prior art keywords
sonidegib
hydrate
salt
occur
pharmaceutically acceptable
Prior art date
Application number
LU92883C
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38668605&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92883(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LU92883I2 publication Critical patent/LU92883I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/75—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LU92883C 2006-05-05 2015-11-20 Sonidégib ou un sel, hydrate ou solvate pharmaceutiquement acceptable qui en dérive LU92883I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79794906P 2006-05-05 2006-05-05

Publications (1)

Publication Number Publication Date
LU92883I2 true LU92883I2 (fr) 2016-01-20

Family

ID=38668605

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92883C LU92883I2 (fr) 2006-05-05 2015-11-20 Sonidégib ou un sel, hydrate ou solvate pharmaceutiquement acceptable qui en dérive

Country Status (44)

Country Link
US (2) US8178563B2 (fr)
EP (2) EP2363393B1 (fr)
JP (2) JP4891396B2 (fr)
KR (1) KR101076943B1 (fr)
CN (2) CN102746285B (fr)
AR (2) AR060858A1 (fr)
AU (1) AU2007247860C1 (fr)
BR (1) BRPI0711333B8 (fr)
CA (1) CA2650248C (fr)
CL (1) CL2007001269A1 (fr)
CR (1) CR10399A (fr)
CU (1) CU23760B7 (fr)
CY (1) CY2015054I1 (fr)
DK (1) DK2021328T3 (fr)
EA (1) EA018302B1 (fr)
EC (1) ECSP088860A (fr)
ES (2) ES2552347T3 (fr)
GE (1) GEP20105103B (fr)
GT (1) GT200800237A (fr)
HN (1) HN2008001652A (fr)
HU (1) HUS1500065I1 (fr)
IL (1) IL194818A (fr)
JO (1) JO2883B1 (fr)
LT (1) LTC2021328I2 (fr)
LU (1) LU92883I2 (fr)
MA (1) MA30426B1 (fr)
ME (1) ME00417B (fr)
MX (1) MX2008014190A (fr)
MY (1) MY153574A (fr)
NL (1) NL300790I1 (fr)
NO (3) NO341215B1 (fr)
NZ (1) NZ572362A (fr)
PE (1) PE20080418A1 (fr)
PL (2) PL2363393T3 (fr)
PT (2) PT2021328E (fr)
SG (1) SG172680A1 (fr)
SI (1) SI2021328T1 (fr)
SM (1) SMP200800056B (fr)
SV (1) SV2008003089A (fr)
TN (1) TNSN08437A1 (fr)
TW (1) TWI369352B (fr)
UA (1) UA93548C2 (fr)
WO (1) WO2007131201A2 (fr)
ZA (1) ZA200808962B (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA93548C2 (uk) * 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
AU2014280951B2 (en) * 2007-06-07 2016-10-13 Sun Pharmaceutical Industries Limited Biphenylcarboxamide derivatives as hedgehog pathway modulators
JP5373777B2 (ja) * 2007-06-07 2013-12-18 アイアールエム・リミテッド・ライアビリティ・カンパニー ヘッジホッグ経路モジュレーターとしてのビフェニルカルボキサミド誘導体
JP2011505341A (ja) * 2007-11-21 2011-02-24 デコード ジェネティクス イーエイチエフ 炎症性、心血管およびｃｎｓ障害を治療するビアリールｐｄｅ４抑制剤
CN101917853B (zh) 2007-12-27 2014-03-19 无限药品股份有限公司 立体选择性还原的方法
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US20090281089A1 (en) * 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
AR073591A1 (es) * 2008-09-17 2010-11-17 Novartis Ag Sales de n-[6-(cis-2,6-dimetil-morfolin-4-il)-piridin-3-il]-2-metil-4'-(trifluorometoxi)-[1,1'-bifenil]-3-carboxamida,composiciones farmaceuticas que las contienen,utiles para el tratamiento de carcinomas.
EP2346499A1 (fr) * 2008-10-01 2011-07-27 Novartis AG Antagonisme smoothened pour le traitement de troubles liés à la voie de signalisation hedgehog
WO2010052448A2 (fr) * 2008-11-05 2010-05-14 Ucb Pharma S.A. Dérivés de pyrazine fusionnés en tant qu'inhibiteurs de kinase
AR077490A1 (es) 2009-07-21 2011-08-31 Novartis Ag Composiciones farmaceuticas topicas para el tratamiento de una condicion hiperproliferativa de la piel
AU2010279325B2 (en) 2009-08-05 2016-10-20 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
US20110039850A1 (en) * 2009-08-12 2011-02-17 Mhairi Copland Leukemia Treatment
BR112012011823A2 (pt) * 2009-11-18 2019-09-24 Novartis Ag métodos e composições para tratar tumores sólidos e outras malignidades
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
US9394313B2 (en) 2010-09-14 2016-07-19 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
CN101993415B (zh) * 2010-09-15 2013-08-14 北京韩美药品有限公司 作为Hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用
US8901133B2 (en) 2010-11-10 2014-12-02 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20180080358A (ko) 2011-01-10 2018-07-11 인피니티 파마슈티칼스, 인코포레이티드 이소퀴놀린온 및 이의 고체 형태의 제조 방법
PH12013502340A1 (en) 2011-06-02 2014-01-06 Novartis Ag Biomarkers for hedgehog inhibitor therapy
EP2734530A1 (fr) 2011-07-19 2014-05-28 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
CN103930422A (zh) 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
CN103998442B (zh) 2011-08-29 2016-09-14 无限药品股份有限公司 杂环化合物及其用途
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2895474B1 (fr) 2012-09-17 2019-12-11 Duke University Modulateurs du récepteur smoothened et leurs procédés d'utilisation
IL291945B2 (en) 2012-11-01 2025-11-01 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
US9844541B2 (en) 2012-11-29 2017-12-19 Strasspharma, Llc Methods of modulating follicle stimulating hormone activity
CN103910736B (zh) * 2013-01-08 2017-11-17 江苏先声药业有限公司 一类二氢吡喃并嘧啶衍生物及其医药应用
WO2014151386A1 (fr) 2013-03-15 2014-09-25 Infinity Pharmaceuticals, Inc. Sels et formes solides d'isoquinolinones et compositions les comprenant et procédés pour les utiliser
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
SG10201709926VA (en) 2013-05-30 2017-12-28 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
WO2015051241A1 (fr) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015092720A1 (fr) * 2013-12-19 2015-06-25 Novartis Ag Métabolites de sonidegib (lde225)
ES2716685T3 (es) 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Moléculas de anticuerpo para PD-1 y usos de las mismas
DK3099717T3 (da) 2014-01-31 2019-07-01 Novartis Ag Antistofmolekyler med tim-3 og anvendelser deraf
TWI777174B (zh) 2014-03-14 2022-09-11 瑞士商諾華公司 針對lag-3之抗體分子及其用途
EP4066834A1 (fr) 2014-03-19 2022-10-05 Infinity Pharmaceuticals, Inc. Composés hétérocycliques pour une utilisation dans le traitement de troubles à médiation pi3k-gamma
JP6377245B2 (ja) 2014-03-24 2018-08-22 グアンドン ジョンシェン ファーマシューティカル カンパニー リミテッド Ｓｍｏ阻害剤としてのキノリン誘導体
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (fr) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Dérivés de pyrimidine ou de pyridine utiles en tant qu'inhibiteurs de pi3k
WO2016054491A1 (fr) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
UY36351A (es) 2014-10-14 2016-06-01 Novartis Ag Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
EP3233918A1 (fr) 2014-12-19 2017-10-25 Novartis AG Polythérapies
CA2979215A1 (fr) 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions et procedes d'activation de la signalisation dependante de « stimulateur de genes d'interferon »
US10266523B2 (en) * 2015-03-30 2019-04-23 Crystal Pharmatech Co., Ltd. Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4′-(trifluoromethoxy) [1,1′-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof
US10369147B2 (en) 2015-06-04 2019-08-06 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
EP3303289A4 (fr) * 2015-06-05 2018-11-14 Dana-Farber Cancer Institute, Inc. Composés et méthodes de traitement du cancer
LT3317301T (lt) 2015-07-29 2021-07-26 Novartis Ag Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
EP3316902A1 (fr) 2015-07-29 2018-05-09 Novartis AG Polythérapies comprenant des molécules d'anticorps contre tim -3
CN108349985A (zh) 2015-09-14 2018-07-31 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
SMT202200118T1 (it) 2015-11-03 2022-05-12 Janssen Biotech Inc Anticorpi che legano specificamente pd-1 e loro usi
WO2017083216A1 (fr) * 2015-11-12 2017-05-18 Merck Sharp & Dohme Corp. Dérivés de cyanopyridine utilisés en tant qu'agonistes des récepteurs bêta x du foie, compositions associées et leur utilisation
ES2986067T3 (es) 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
WO2017139497A1 (fr) 2016-02-11 2017-08-17 PellePharm, Inc. Inhibiteur de la voie hedgehog destiné à être utilisé pour soulager et traiter le prurit ou les démangeaisons
WO2017163258A1 (fr) * 2016-03-22 2017-09-28 Msn Laboratories Private Limited Procédé de préparation de n-[6-(cis-2,6-diméthylmorpholin-4-yl)pyridine-3-yl]-2- méthyl-4'-(trifluorométhoxy) [1,1'-biphényl]-3-carboxamide et de ses polymorphes
WO2017214269A1 (fr) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
CA3028718A1 (fr) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Polytherapies
WO2018009466A1 (fr) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
WO2021261601A1 (fr) 2020-06-26 2021-12-30 ラクオリア創薬株式会社 Méthode de sélection d'un patient cancéreux pour lequel une polythérapie d'un rétinoïde et d'un agent de traitement du cancer sera efficace, et médicament combiné d'un rétinoïde et d'un agent de traitement du cancer
KR20230153959A (ko) * 2022-04-29 2023-11-07 제일약품주식회사 신규한 pim 키나아제 억제 화합물 및 이의 용도

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
JP2001519345A (ja) 1997-10-02 2001-10-23 メルク エンド カムパニー インコーポレーテッド プレニルタンパク質トランスフェラーゼの阻害剤
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US6335459B1 (en) 1998-12-23 2002-01-01 Syntex (U.S.A.) Llc Aryl carboxylic acid and aryl tetrazole derivatives as IP receptor modulators
WO2001044172A1 (fr) 1999-12-15 2001-06-21 Axys Pharmaceuticals, Inc. Salicylamides utiles en tant qu'inhibiteurs des serines proteases
JP2004501062A (ja) 1999-12-17 2004-01-15 アライアッド・ファーマシューティカルズ・インコーポレーテッド 新規プリン類
US20030187261A1 (en) 2000-01-07 2003-10-02 Libor Havlicek Purine derivatives, process for their preparation and use thereof
US6699997B2 (en) * 2000-06-28 2004-03-02 Teva Pharmaceutical Industries Ltd. Carvedilol
GB0022438D0 (en) 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
JP2002338537A (ja) * 2001-05-16 2002-11-27 Mitsubishi Pharma Corp アミド化合物およびその医薬用途
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
JP2005538975A (ja) 2002-07-03 2005-12-22 アステックス テクノロジー リミテッド ｐ３８ＭＡＰキナーゼ阻害薬としての３−（ヘテロ）アリールメトキシピリジン類およびそれらの類縁体
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2005000309A2 (fr) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Composes chimiques
CA2531796A1 (fr) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Composes aryle et heteroaryle, compositions et procedes d'utilisation
WO2005020892A2 (fr) 2003-08-08 2005-03-10 Mitochroma Research, Inc. Compositions pharmaceutiques et procedes de modulation metabolique
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
EP1670787B1 (fr) 2003-09-11 2012-05-30 iTherX Pharma, Inc. Inhibiteurs des cytokines
WO2005030206A1 (fr) * 2003-09-24 2005-04-07 Imclone Systems Incorporated Derives d'aryl-1,3-azole et procedes permettant d'inhiber l'activite de l'heparanase
WO2005033288A2 (fr) * 2003-09-29 2005-04-14 The Johns Hopkins University Antagonistes de la voie hedgehog
AR046698A1 (es) 2003-11-11 2005-12-21 Ishihara Sangyo Kaisha Derivado bifenilo o su sal, y pesticida que lo contienen como un ingrediente activo
WO2005063258A1 (fr) 2003-12-22 2005-07-14 Gilead Sciences, Inc. Conjugues de phosphonate inhibant la kinase
AU2005325267B2 (en) * 2004-04-30 2010-11-04 Curis Inc. Quinoxaline inhibitors of the hedgehog signalling pathway
US7683097B2 (en) 2004-05-27 2010-03-23 Propharmacon Inc. Topoisomerase inhibitors
KR20170001725A (ko) * 2004-09-02 2017-01-04 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
FR2876583B1 (fr) 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
ATE502025T1 (de) * 2004-10-19 2011-04-15 Compass Pharmaceuticals Llc Arylcarboxamide und ihre verwendung als antitumormittel
GT200500321A (es) 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
EP1844003A4 (fr) 2005-01-27 2010-09-22 Astrazeneca Ab Nouveaux composes biaromatiques, inhibiteurs du recepteur p2x7
US20060281791A1 (en) 2005-04-29 2006-12-14 Children's Medical Center Corporation Methods of increasing proliferation of adult mammalian cardiomyocytes through p38 map kinase inhibition
CA2605272C (fr) 2005-05-18 2013-12-10 Janssen Pharmaceutica N.V. Derives substitues d'aminopropenyl-piperidine ou de morpholine utilises en tant qu'inhibiteurs de l'histone-desacetylase
WO2007008627A2 (fr) 2005-07-07 2007-01-18 Abbott Laboratories Promoteurs d'apoptose
WO2007031791A1 (fr) * 2005-09-16 2007-03-22 Arrow Therapeutics Limited Dérivés de biphényle et leur utilisation dans le traitement de l'hépatite c
UA93548C2 (uk) * 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2008008059A1 (fr) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Agents anti-cancer et leurs utilisations
PE20080948A1 (es) 2006-07-25 2008-09-10 Irm Llc Derivados de imidazol como moduladores de la senda de hedgehog
PL2076268T3 (pl) 2006-10-19 2013-06-28 Genzyme Corp Roskowityna do leczenia pewnych chorób torbielowatych
DE102006062203A1 (de) 2006-12-22 2008-06-26 Curacyte Discovery Gmbh Substituierte 5H-Pyrimido[5,4-b]indole als Induktoren der Apoptose bei B-CLL Zellen
JP5373777B2 (ja) 2007-06-07 2013-12-18 アイアールエム・リミテッド・ライアビリティ・カンパニー ヘッジホッグ経路モジュレーターとしてのビフェニルカルボキサミド誘導体
US8124605B2 (en) 2007-07-06 2012-02-28 Kinex Pharmaceuticals, Llc Compositions and methods for modulating a kinase cascade
WO2009075874A1 (fr) 2007-12-13 2009-06-18 Amgen Inc. Modulateurs de la gamma-sécrétase
WO2009078992A1 (fr) 2007-12-17 2009-06-25 Amgen Inc. Composés tricycliques linéaires utilisés comme inhibiteurs de la kinase p38

Also Published As

Publication number Publication date
TNSN08437A1 (en) 2010-04-14
WO2007131201A3 (fr) 2008-03-06
HUS1500065I1 (hu) 2016-01-28
EP2363393A1 (fr) 2011-09-07
UA93548C2 (uk) 2011-02-25
IL194818A0 (en) 2009-09-22
HN2008001652A (es) 2011-07-14
AR109423A2 (es) 2018-11-28
CL2007001269A1 (es) 2008-03-14
US20090203666A1 (en) 2009-08-13
JO2883B1 (en) 2015-03-15
NO341215B1 (no) 2017-09-11
MY153574A (en) 2015-02-27
RU2008147663A (ru) 2010-06-10
US20120196849A1 (en) 2012-08-02
CA2650248C (fr) 2011-11-29
KR20080108343A (ko) 2008-12-12
CU20080202A7 (es) 2011-02-24
TWI369352B (en) 2012-08-01
JP2012017333A (ja) 2012-01-26
PL2021328T3 (pl) 2013-08-30
LTPA2015051I1 (lt) 2015-12-15
US8178563B2 (en) 2012-05-15
NO20085059L (no) 2009-02-04
AU2007247860B2 (en) 2011-06-09
NO20171395A1 (no) 2017-08-29
JP2009536220A (ja) 2009-10-08
NO2018021I1 (no) 2018-06-28
PT2363393E (pt) 2015-11-19
NZ572362A (en) 2010-10-29
NO341889B1 (no) 2018-02-12
WO2007131201A2 (fr) 2007-11-15
MA30426B1 (fr) 2009-05-04
AR060858A1 (es) 2008-07-16
NL300790I2 (fr) 2016-03-15
CN101437800A (zh) 2009-05-20
HK1127043A1 (en) 2009-09-18
CN102746285A (zh) 2012-10-24
ES2422557T3 (es) 2013-09-12
SMAP200800056A (it) 2008-10-29
CY2015054I2 (el) 2016-12-14
PL2363393T3 (pl) 2016-03-31
EP2021328A2 (fr) 2009-02-11
CN102746285B (zh) 2022-01-14
IL194818A (en) 2013-12-31
EA200870504A1 (ru) 2009-04-28
BRPI0711333B8 (pt) 2021-05-25
SMP200800056B (it) 2009-11-06
NL300790I1 (fr) 2016-03-15
EP2363393B1 (fr) 2015-08-12
PT2021328E (pt) 2013-06-28
BRPI0711333B1 (pt) 2020-11-17
CY2015054I1 (el) 2016-12-14
ME00417B (fr) 2011-10-10
GEP20105103B (en) 2010-10-25
JP5603308B2 (ja) 2014-10-08
JP4891396B2 (ja) 2012-03-07
SG172680A1 (en) 2011-07-28
GT200800237A (es) 2009-04-29
RU2413718C2 (ru) 2011-03-10
AU2007247860C1 (en) 2012-01-12
EA018302B1 (ru) 2013-07-30
AU2007247860A1 (en) 2007-11-15
ZA200808962B (en) 2009-11-25
ECSP088860A (es) 2008-12-30
CR10399A (es) 2008-12-03
KR101076943B1 (ko) 2011-10-26
SI2021328T1 (sl) 2013-08-30
PE20080418A1 (es) 2008-06-09
ES2552347T3 (es) 2015-11-27
CA2650248A1 (fr) 2007-11-15
CU23760B7 (es) 2012-01-31
BRPI0711333A2 (pt) 2011-08-30
LTC2021328I2 (lt) 2017-06-26
EP2021328B1 (fr) 2013-04-03
MX2008014190A (es) 2009-02-04
TW200811132A (en) 2008-03-01
DK2021328T3 (da) 2013-06-24
SV2008003089A (es) 2010-01-12

Similar Documents

Publication Publication Date Title
LU92883I2 (fr) Sonidégib ou un sel, hydrate ou solvate pharmaceutiquement acceptable qui en dérive
FIC20220043I1 (fi) Difelikefaliini, valinnaisesti farmaseuttisesti hyväksyttävänä suolana, hydraattina, solvaattina, happosuolahydraattina tai N-oksidina
NO2023047I1 (no) Cedazuridine, or a pharmaceutically acceptable salt thereof
NO2020038I1 (no) Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt
LU92668I2 (fr) Ombitasvir, ou un sel pharmaceutiquement acceptable qui en dérive (viekirax)
LU93327I2 (fr) Opicapone ou un sel pharmaceutiquement acceptable de celui-ci
LU92667I2 (fr) Paritaprevir, ou un sel ou ester pharmaceutiquement acceptable qui en dérive (viekirax)
AP2369A (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors.
LU92446I2 (fr) Dolutégravir ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, y compris de dolutégravir de sodium
EP2015752A4 (fr) Antagonistes de kinase p13
NL2000627A1 (nl) Cycloalkylaminoderivaten.
NL2000480A1 (nl) Nieuwe farmaceutische middelen.
NO2013008I1 (no) Krizotinib eller et farmasøytisk akseptabelt salt,hydrat eller solvat derav
SI2201012T1 (sl) Derivati pirolo(2,3-D)pirimidina kot inhibitorji proteina kinaze B
FR2903733B1 (fr) Turbomoteur pour aeronef.
ZA200903523B (en) Poly-TLR antagonist
IL193427A0 (en) Polypeptide antagonist
ZA200804667B (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
ITMC20060051U1 (it) Sacconi per copertura palmizi.
ITMC20060178A1 (it) Sacconi per copertura palmizi.
ES1060713Y (es) Batea poligonal para cria de bivalvos en mar abierto.
ITVE20060054A1 (it) Tegola conversa per diagonali.
ES1061007Y (es) Traje para buceo.
ITBZ20050060A1 (it) Apparecchiatura per barbecue.
ITPD20040243A1 (it) Inserto per sottotacchi.